TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27950663

Group type: EXPERIMENTAL
Intervention: EGF 50 mug/ml
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 16634381

Group type: EXPERIMENTAL
Intervention: Nurse-led pre-operative assessment
Number of subjects: 595

Group type: COMPARATOR
Intervention: Junior doctor-led pre-operative assessment (Control)
Number of subjects: 595
Study: 12928686

Group type: EXPERIMENTAL
Intervention: Tropicamide 1%
Number of subjects: 28
Study: 10789889

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg) administered prior to both encoding and retrieval
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo administered prior to both encoding and retrieval
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alcohol administered prior to encoding and retrieval
Number of subjects: 48
Study: 8918499

Group type: EXPERIMENTAL
Intervention: Breast-conservation treatment (lumpectomy) in node-negative trials
Number of subjects: 5172

Group type: EXPERIMENTAL
Intervention: Breast-conservation treatment (lumpectomy) in node-positive trials
Number of subjects: 5172

Group type: EXPERIMENTAL
Intervention: Lumpectomy use with tumor size <= 1 cm and negative nodes
Number of subjects: 5172

Group type: EXPERIMENTAL
Intervention: Lumpectomy rates across systemic risk strata
Number of subjects: 5172

Group type: EXPERIMENTAL
Intervention: Predictors of lower lumpectomy use
Number of subjects: 5172
Study: 1442657

Group type: EXPERIMENTAL
Intervention: Guar gum (added to diet four times per day for 6 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (added to diet four times per day for 6 weeks)
Number of subjects: 0
Study: 3880685

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihydralazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30663187

Group type: EXPERIMENTAL
Intervention: Continuous CGM (80% of the time)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Discontinuous CGM (40% of the time)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Return to self-monitoring of blood glucose
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: All groups (after 3 months of RT-CGM)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Full-time RT-CGM for 3 months
Number of subjects: 151
Study: 29715529

Group type: EXPERIMENTAL
Intervention: Project Health
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Healthy Weight
Number of subjects: 364

Group type: COMPARATOR
Intervention: Video control
Number of subjects: 364
Study: 26924051

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1255
Study: 24271056

Group type: EXPERIMENTAL
Intervention: Tamoxifen followed by exemestane
Number of subjects: 1502

Group type: COMPARATOR
Intervention: Exemestane alone
Number of subjects: 1502

Group type: EXPERIMENTAL
Intervention: Sequential therapy (tamoxifen followed by exemestane)
Number of subjects: 1502
Study: 22106843

Group type: EXPERIMENTAL
Intervention: MAP0004
Number of subjects: 418

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study: 21055087

Group type: EXPERIMENTAL
Intervention: Oral fluconazole prophylaxis
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (no fluconazole prophylaxis)
Number of subjects: 224
Study: 17546459

Group type: EXPERIMENTAL
Intervention: Exercise with prior expiratory muscle fatigue (EMF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control exercise (without prior EMF)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise with prior EMF
Number of subjects: 12
Study: 16266450

Group type: EXPERIMENTAL
Intervention: Prompt fibrinolytic therapy
Number of subjects: 1120

Group type: COMPARATOR
Intervention: UK group
Number of subjects: 1120

Group type: COMPARATOR
Intervention: SK group
Number of subjects: 1120

Group type: COMPARATOR
Intervention: rt-PA group
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Aborted AMI patients
Number of subjects: 1120
Study: 12049013

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Open cholecystectomy (control group)
Number of subjects: 70
Study: 10381663

Group type: EXPERIMENTAL
Intervention: Reoperation
Number of subjects: 55

Group type: COMPARATOR
Intervention: Botulinum toxin injection
Number of subjects: 55
Study: 7573843

Group type: EXPERIMENTAL
Intervention: FPANS 100 micrograms od
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: FPANS 200 micrograms od
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo od
Number of subjects: 143
Study: 2324541

Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccine (ProHibit)
Number of subjects: 50
Study: 371021

Group type: EXPERIMENTAL
Intervention: Oxprenolol 160 mg in a slow-release formulation with cyclopenthiazide 0.25 mg and potassium chloride 600 mg given once daily
Number of subjects: 238

Group type: COMPARATOR
Intervention: Methyldopa 250 mg 3 times daily
Number of subjects: 238
Study: 31392790

Group type: EXPERIMENTAL
Intervention: Hip exercises
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Knee exercises
Number of subjects: 29
Study: 27751610

Group type: EXPERIMENTAL
Intervention: 3 exchanges
Number of subjects: 139

Group type: COMPARATOR
Intervention: 4 exchanges
Number of subjects: 139
Study: 25318667

Group type: EXPERIMENTAL
Intervention: flow‐SNIPPV
Number of subjects: 19

Group type: COMPARATOR
Intervention: NIPPV
Number of subjects: 19

Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 19
Study: 23425607

Group type: EXPERIMENTAL
Intervention: MMRV(new WS) vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: MMRV vaccine
Number of subjects: 0
Study: 22211198

Group type: EXPERIMENTAL
Intervention: Radial shock wave therapy in addition to physical therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 26
Study: 19826291

Group type: EXPERIMENTAL
Intervention: Treadmill running (TR) for 20 minutes at approximately 70-80% of heart rate reserve
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE) for 20 minutes (20 repetitions at 40% of 1 repetition maximum)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control session without exercise (CON)
Number of subjects: 15
Study: 16506871

Group type: EXPERIMENTAL
Intervention: High-intensity inspiratory muscle training (IMT) at 80% of maximal effort for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 20
Study: 12801243

Group type: EXPERIMENTAL
Intervention: Uric acid (UA) 0.5 g in 250 ml of 0.1% lithium carbonate/4% dextrose vehicle
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle alone (control)
Number of subjects: 20
Study: 11063279

Group type: EXPERIMENTAL
Intervention: Intensive multifactorial treatment (lifestyle advice, prescription of aspirin and ACE‐inhibitors, protocol‐driven tight control of blood glucose, blood pressure and cholesterol)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Conventional treatment (according to current national guidelines)
Number of subjects: 3000
Study: 9115065

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg) for 45 days
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo for 45 days
Number of subjects: 89
Study: 1492231

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose-intensive chemotherapy regimens supported by GM-CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 3890909

Group type: EXPERIMENTAL
Intervention: Etomidate (continuous infusion increasing from 0.01 mg kg‐1 min‐1 to 0.05 mg kg‐1 min‐1 over 50 min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (equivalent volume to etomidate)
Number of subjects: 14
Study: 31912491

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) for 6 weeks as adjunctive treatment to supervised exercise.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) for 6 weeks.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Supervised exercise programme only.
Number of subjects: 62
Study: 31046522

Group type: EXPERIMENTAL
Intervention: Euhydration (EU)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hypohydration (HH)
Number of subjects: 10
Study: 28699973

Group type: EXPERIMENTAL
Intervention: Intervention group focusing on lifestyle changes, physical activities, and nutritional education, with activities occurring monthly in the school's multimedia room or sports court.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving usual recommendations by the school.
Number of subjects: 0
Study: 27244537

Group type: EXPERIMENTAL
Intervention: 2 courses of S-1 plus cisplatin (SC)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 4 courses of S-1 plus cisplatin (SC)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 2 courses of paclitaxel plus cisplatin (PC)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 4 courses of paclitaxel plus cisplatin (PC)
Number of subjects: 83
Study: 24835418

Group type: EXPERIMENTAL
Intervention: Open flap debridement (OFD) in endodontically treated teeth with chlorhexidine (CHX) placed in the coronal space (test)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Open flap debridement (OFD) in endodontically treated teeth (control)
Number of subjects: 31
Study: 23011712

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg; maximum dose, 20 mg)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 20212252

Group type: COMPARATOR
Intervention: Continuous 6-mercaptopurine (6-MP) and weekly methotrexate (MTX)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Intermittent 6-mercaptopurine (100 mg/m(2)/d for 10 days, with 11 days resting) and MTX (200 mg/m(2) every 3 weeks)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Intermittent regimen (group 2) vs Continuous regimen (group 1) in boys
Number of subjects: 544

Group type: COMPARATOR
Intervention: Intermittent regimen (group 2) vs Continuous regimen (group 1) in girls
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Intermittent 6-mercaptopurine and MTX
Number of subjects: 544
Study: 17621202

Group type: EXPERIMENTAL
Intervention: Shaved group (371 patients)
Number of subjects: 789

Group type: COMPARATOR
Intervention: Unshaved group (418 patients)
Number of subjects: 789
Study: 16236917

Group type: EXPERIMENTAL
Intervention: Supported arm exercise training plus general physiotherapy (gPT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: General physiotherapy (gPT) alone
Number of subjects: 66
Study: 11869857

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Model prediction based on NYHA and LAT area
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Model performance in validating sample
Number of subjects: 108
Study: 10609427

Group type: EXPERIMENTAL
Intervention: Offset control over gas inhalation
Number of subjects: 30

Group type: COMPARATOR
Intervention: No offset control over gas inhalation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Offset control in Phase I
Number of subjects: 30

Group type: COMPARATOR
Intervention: No offset control in Phase I
Number of subjects: 30
Study: 7538925

Group type: EXPERIMENTAL
Intervention: Abnormal ALT
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal ALT
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Abnormal LFTs (White Caucasians)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal LFTs (White Caucasians)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Abnormal LFTs (Asians)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal LFTs (Asians)
Number of subjects: 200
Study: 2317427

Group type: EXPERIMENTAL
Intervention: Nicardipine 15 micrograms kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nicardipine 30 micrograms kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study: 7426219

Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg kg‐1 i.v. (group I)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Gallamine 0.3 mg kg‐1 i.v. (group II)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg kg‐1 i.m. and gallamine 0.3 mg kg‐1 i.v. (group III)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg kg‐1 i.v. and gallamine 0.3 mg kg‐1 i.v. (group IV)
Number of subjects: 80
Study: 31373921

Group type: EXPERIMENTAL
Intervention: Instrumental variable (IV) estimators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher ages at study inclusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-sample vs two-sample estimation
Number of subjects: 0
Study: 28112773

Group type: EXPERIMENTAL
Intervention: Soccer training plus calorie‐restricted diet (SDG)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Diet group (DG)
Number of subjects: 51
Study: 26435849

Group type: EXPERIMENTAL
Intervention: Litramine (3 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23768279

Group type: EXPERIMENTAL
Intervention: Visceral manipulation (VM) added to standard physiotherapy treatment regimen.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard physiotherapy treatment regimen (manual therapy, specific exercise, functional exercise prescription).
Number of subjects: 0
Study: 21417617

Group type: EXPERIMENTAL
Intervention: Controlled release liquid form of codeine (69.7 mg every 12 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Codeine in solution (23.2 mg every 4 h)
Number of subjects: 0
Study: 19515791

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) for 2 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Obese group (including T2DM)
Number of subjects: 54

Group type: COMPARATOR
Intervention: T2DM group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Correlation of serum MIC‐1 levels
Number of subjects: 54
Study: 18393643

Group type: EXPERIMENTAL
Intervention: 10 mL prilocaine infiltration
Number of subjects: 121

Group type: COMPARATOR
Intervention: 20 mL prilocaine infiltration
Number of subjects: 121
Study: 16239807

Group type: EXPERIMENTAL
Intervention: Shock wave therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 49
Study: 12172339

Group type: EXPERIMENTAL
Intervention: Reboxetine 8 to 10 mg/day
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 to 40 mg/day
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study: 10692976

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) and 1000 mg calcium per day (n = 10)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 1000 mg calcium per day (n = 14)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No treatment (control group, n = 10)
Number of subjects: 34
Study: 7476595

Group type: EXPERIMENTAL
Intervention: Pantothenic acid replacement therapy, dosage and duration not specified
Number of subjects: 0
Study: 2337215

Group type: EXPERIMENTAL
Intervention: Nefopam 20 mg by intramuscular injection 6 hourly for 24 hours
Number of subjects: 84

Group type: COMPARATOR
Intervention: Diclofenac 75 mg 12-hourly and placebo injections at 6 and 18 hours
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combination of nefopam and diclofenac
Number of subjects: 84
Study: 6996897

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg intravenously)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Histamine (0.13 microgram/kg/min for 20 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Histamine with Cimetidine pretreatment
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Histamine and Cimetidine
Number of subjects: 6
Study: 30661768

Group type: EXPERIMENTAL
Intervention: Protamine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (no protamine)
Number of subjects: 150
Study: 26873789

Group type: EXPERIMENTAL
Intervention: Lean-seafood diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonseafood diet
Number of subjects: 20
Study: 24898987

Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 51
Study: 22305043

Group type: EXPERIMENTAL
Intervention: Sunscreen availability in locker rooms and golf bags
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no sunscreen availability)
Number of subjects: 83
Study: 20128823

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 18832244

Group type: EXPERIMENTAL
Intervention: Maraviroc once daily
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Maraviroc twice daily
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1049
Study: 16837136

Group type: EXPERIMENTAL
Intervention: Silicone gel sheeting (Cica-Care) applied 24h per day for 6 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control intervention (daily massage for 15 min)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Silicone gel sheeting (Cica-Care)
Number of subjects: 45
Study: 12847427

Group type: EXPERIMENTAL
Intervention: Educational brochure and video (CALM approach)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 216
Study: 10668125

Group type: EXPERIMENTAL
Intervention: Improved sleep hygiene instructions (Group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No instructions on improving sleep hygiene (Group B)
Number of subjects: 70
Study: 7562017

Group type: EXPERIMENTAL
Intervention: One-day antibiotic prophylaxis (clindamycin and cefonicid)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Three-day antibiotic prophylaxis (clindamycin and cefonicid)
Number of subjects: 126
Study: 1935632

Group type: EXPERIMENTAL
Intervention: CO2‐containing water (1400 mg CO2/kg H2O) at 34 degrees C for 20 minutes
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fresh water at 34 degrees C for 20 minutes
Number of subjects: 16
Study: 6988950

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg) and tinidazole (2 g)
Number of subjects: 307
Study: 31469512

Group type: EXPERIMENTAL
Intervention: Pseudoisochromatic (PIC) test
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Mollon‐Reffin minimalist (MRM) test
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cambridge Colour Test (CCT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Age effect on CCT
Number of subjects: 71
Study: 31164362

Group type: EXPERIMENTAL
Intervention: Goal-setting intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Usual care planning (Control)
Number of subjects: 52
Study: 28270129

Group type: EXPERIMENTAL
Intervention: Digital intake approach facilitated by Routine Outcome Monitoring (ROM), peer support, and training of clinicians
Number of subjects: 176

Group type: COMPARATOR
Intervention: Intake as usual
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Digital intake approach
Number of subjects: 176
Study: 25933795

Group type: EXPERIMENTAL
Intervention: Varenicline (VAR) 1 mg BID
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) 25 mg QD
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of VAR + NTX
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 23763614

Group type: EXPERIMENTAL
Intervention: VeinViewer®
Number of subjects: 1913

Group type: EXPERIMENTAL
Intervention: AccuVein® AV300
Number of subjects: 1913

Group type: EXPERIMENTAL
Intervention: VascuLuminator Vision®
Number of subjects: 1913

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1913
Study: 21819569

Group type: EXPERIMENTAL
Intervention: Telehealth and telecare
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19548064

Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronate (HA) injections
Number of subjects: 720
Study: 17109866

Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Simvastatin (40 mg/day)
Number of subjects: 52
Study: 15118606

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study: 11693870

Group type: EXPERIMENTAL
Intervention: N,N-diethyl-M-toluamide (DEET) 1.7 g/day
Number of subjects: 897
Study: 9051820

Group type: COMPARATOR
Intervention: Defibrillation without pulse checks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Defibrillation with pulse checks by an assistant
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Defibrillation with pulse checks by the participant
Number of subjects: 20
Study: 8189337

Group type: EXPERIMENTAL
Intervention: Role-informed malingerer group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PTSD patients
Number of subjects: 60
Study: 3300157

Group type: EXPERIMENTAL
Intervention: oxandrolone, 0.125 mg/kg/day (Group 2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: somatrem, 0.125 mg/kg 3 times/week (Group 3)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combination of somatrem and oxandrolone (Group 4)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: somatrem, 0.125 mg/kg 3 times/week and oxandrolone, 0.0625 mg/kg/day (after 12-20 months for Groups 1, 2, and 4)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: somatrem and combination groups
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 70
Study: 31800354

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 300 mg/day (range 100-600 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol (THC) 10 mg/day (range 5-30 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Total Symptom Distress Scores (TSDS) measured using the Edmonton Symptom Assessment Scale
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Adverse Events (AEs)
Number of subjects: 21